Project description:The goal of this study is to investigate the molecular mechanisms of LIF action on pancreatic cancer cells in the classical pancreatic ductal adenocarcinoma mouse model KrasLSL-G12D;Tp53f/f;Rosa26LSL-Luc;Pdx1-Cre mice EpCAM+ pancreatic cancer cells were isolated from pancreatic tumors developped in KrasLSL-G12D;Tp53f/f;Rosa26LSL-Luc;Pdx1-Cre mice treated with either gemcitabine plus control IgG or gemcitabine plus anti-LIF antibody by FACS
Project description:This study investigated the impact of an anti-LCN2 monoclonal antibody on STR-authenticated HeLa cells using a xenograft model in athymic nude mice. Treatment of tumors with anti-LCN2 antibody resulted in 39 – 60% reduction in tumor volume. RNA extracted from the tumors post-treatment was sequenced and aligned to human and mouse genome separately. Differential expression analysis of human mapped overexpressed genes in treated tumor revealed suppression of pro-tumorigenic TNF- and IL17 signalling pathways, whereas the corresponding mouse-mapped genes indicated pathways including activation of T-cells and T-cell mediated killing in treated tumors. M2 mouse macrophage markers showed a decline under treatment signifying tumor regression. This observed T-cell activation and debilitation of M2 mouse macrophages by anti-LCN2 underlies its potential as an immune sensitizer that can potentially devour tumor cells through T-cell mediated cytotoxicity.
Project description:This study was designed to explore how targeting Slc7a11 affected CD8+ T cell differentiation and function using a mouse colorectal cancer model. Single-cell RNA-seq was used to monitor tumor-infiltrating CD8+ T cells from Slc7a11 knockout and wild-type mouse tumor models treated with IgG control or anti-Ctla4 antibody.
Project description:This study was designed to explore how targeting Slc7a11 affected CD8+ T cell differentiation and function using a mouse colorectal cancer model. TCR-seq was used to profile T cell receptor repertoires in mouse tumor-infiltrating T cells from wild-type and Slc7a11 knockout tumor models treated with IgG control or anti-Ctla4 antibody.
Project description:Identification of beta-catenin interacting proteins via affinity purification with anti-beta-catenin antibody or IgG control in BCR-ABL1 transformed murine pre-B cells with induced beta-catenin activation via CTNNB1 exon3 fl/fl + Cre.
Project description:Identification of beta-catenin interacting proteins via affinity purification with anti-beta-catenin antibody or IgG control in BCR-ABL1 transformed murine pre-B cells with induced beta-catenin activation via CTNNB1 exon3 fl/fl + Cre.